Jeremiah O'neill
About Jeremiah O'neill
Jeremiah O'Neill is the Associate Director, Medical Lead, Oncology, UK/I at Bristol Myers Squibb, with extensive experience in oncology and immunology.
Title and Current Role
Jeremiah O'neill is currently the Associate Director, Medical Lead, Oncology, UK/I at Bristol Myers Squibb. His role emphasizes leadership in medical affairs within the oncology field, specifically for the UK and Ireland markets.
Professional Background
Jeremiah O'neill has an extensive professional background in pharmaceutical and clinical pharmacy roles. Since 2015, he has been with Bristol Myers Squibb, holding various positions: Medical Writer, Oncology, Immunology (2015-2016), Code Review Manager (Medical Affairs Final Signatory), Oncology (2016-2019), Disease Area Specialist, Immunology (2019-2020), Senior Disease Area Specialist, Immunology (2020-2021). Prior to these roles, he worked as a Clinical Pharmacist at South London and Maudsley NHS Foundation Trust and Barts Health NHS Trust.
Education and Expertise
Jeremiah O'neill earned a Master's Degree in Pharmacy from Robert Gordon University (2008-2012) and a Postgraduate Certificate in Clinical Pharmacy from Keele University (2015-2017). His academic credentials lay a foundational understanding of pharmacy, which he has further developed through extensive professional experience in both oncology and immunology.
Experience in Oncology and Immunology
Jeremiah O'neill's expertise in oncology and immunology has been honed through various roles at Bristol Myers Squibb. As a Medical Writer and Code Review Manager (Medical Affairs Final Signatory) in Oncology and Immunology, he has developed substantial knowledge and skills in these areas. In his subsequent roles as Disease Area Specialist and Senior Disease Area Specialist in Immunology, he has further deepened his expertise and leadership within the medical field.
Career Progression at Bristol Myers Squibb
Jeremiah O'neill's career at Bristol Myers Squibb highlights a clear progression of responsibilities and expertise. Starting as a Medical Writer in 2015, he moved to Code Review Manager (Medical Affairs Final Signatory), Oncology by 2016. He then transitioned to roles focused on immunology, first as Disease Area Specialist (2019-2020) and later as Senior Disease Area Specialist (2020-2021). His current role as Associate Director, Medical Lead, Oncology, UK/I, marks his ascent to a significant leadership position within the company.